Your browser doesn't support javascript.
loading
Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).
Chalmers, J R; Thomas, K S; Apfelbacher, C; Williams, H C; Prinsen, C A; Spuls, P I; Simpson, E; Gerbens, L A A; Boers, M; Barbarot, S; Stalder, J F; Abuabara, K; Aoki, V; Ardeleanu, M; Armstrong, J; Bang, B; Berents, T L; Burton, T; Butler, L; Chubachi, T; Cresswell-Melville, A; DeLozier, A; Eckert, L; Eichenfield, L; Flohr, C; Futamura, M; Gadkari, A; Gjerde, E S; van Halewijn, K F; Hawkes, C; Howells, L; Howie, L; Humphreys, R; Ishii, H A; Kataoka, Y; Katayama, I; Kouwenhoven, W; Langan, S M; Leshem, Y A; Merhand, S; Mina-Osorio, P; Murota, H; Nakahara, T; Nunes, F P; Nygaard, U; Nygårdas, M; Ohya, Y; Ono, E; Rehbinder, E; Rogers, N K.
Affiliation
  • Chalmers JR; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Thomas KS; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Apfelbacher C; Medical Sociology, Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
  • Williams HC; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Prinsen CA; Department of Epidemiology and Biostatistics, EMGO+ Institute for Health and Care Research, VU University Medical Center, Amsterdam, the Netherlands.
  • Spuls PI; Department of Dermatology, Academic Medical Center, Amsterdam, the Netherlands.
  • Simpson E; Department of Dermatology, Oregon Health and Science University, Portland, OR, U.S.A.
  • Gerbens LAA; Department of Dermatology, Academic Medical Center, Amsterdam, the Netherlands.
  • Boers M; VU University Medical Center, Amsterdam, the Netherlands.
  • Barbarot S; Department of Dermatology, Nantes University Hospital (CHU de Nantes), France.
  • Stalder JF; Department of Dermatology, Nantes University Hospital (CHU de Nantes), France.
  • Abuabara K; Department of Dermatology, University of California San Francisco, San Francisco, CA, U.S.A.
  • Aoki V; University of São Paulo Medical School, São Paulo, Brazil.
  • Ardeleanu M; Regeneron Pharmaceuticals, Tarrytown, NY, U.S.A.
  • Armstrong J; Galderma, Paris, France.
  • Bang B; LEO Pharma, Ballerup, Denmark.
  • Berents TL; Oslo University Hospital, Oslo, Norway.
  • Burton T; Patient, Nottingham, U.K.
  • Butler L; National Eczema Association, San Rafael, CA, U.S.A.
  • Chubachi T; GlaxoSmithKline, Research Triangle Park, NC, U.S.A.
  • Cresswell-Melville A; Eczema Society of Canada, Keswick, ON, Canada.
  • DeLozier A; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Eckert L; Sanofi, Chilly-Mazarin, France.
  • Eichenfield L; Rady Children's Hospital, University of California San Francisco, San Diego, CA, U.S.A.
  • Flohr C; St John's Institute of Dermatology, St Thomas' Hospital, London, U.K.
  • Futamura M; Nagoya Medical Center, Nagoya, Japan.
  • Gadkari A; Regeneron Pharmaceuticals, Tarrytown, NY, U.S.A.
  • Gjerde ES; The Psoriasis and Eczema Association of Norway, Oslo, Norway.
  • van Halewijn KF; Erasmus MC, University Medical Centre, Rotterdam, the Netherlands.
  • Hawkes C; GlaxoSmithKline, Uxbridge, U.K.
  • Howells L; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
  • Howie L; Global Parents for Eczema Research, Brisbane, Australia.
  • Humphreys R; National Eczema Society, London, U.K.
  • Ishii HA; Brazilian Atopic Dermatitis Association (AADA), São Paulo, Brazil.
  • Kataoka Y; Osaka Prefectural Medical Center for Respiratory and Allergic Disease, Osaka, Japan.
  • Katayama I; Osaka University, Osaka, Japan.
  • Kouwenhoven W; Dutch Association for People with Atopic Dermatitis, Nijkerk, the Netherlands.
  • Langan SM; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, U.K.
  • Leshem YA; Beilinson Hospital and Tel Aviv University, Petah Tikva and Tel Aviv, Israel.
  • Merhand S; Association Française de l'Eczéma, Redon, France.
  • Mina-Osorio P; Regeneron Pharmaceuticals, Tarrytown, NY, U.S.A.
  • Murota H; Department of Dermatology, Osaka University, Suita, Japan.
  • Nakahara T; Department of Dermatology, Kyushu University, Fukuoka, Japan.
  • Nunes FP; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Nygaard U; Eli Lilly and Company, Indianapolis, IN, U.S.A.
  • Nygårdas M; Sanofi Genzyme, Stockholm, Sweden.
  • Ohya Y; National Centre for Child Health and Development, Tokyo, Japan.
  • Ono E; Osaka University, Osaka, Japan.
  • Rehbinder E; Department of Dermatology, Oslo University Hospital, Oslo, Norway.
  • Rogers NK; Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, U.K.
Br J Dermatol ; 178(5): e332-e341, 2018 05.
Article in En | MEDLINE | ID: mdl-29672835
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Dermatitis, Atopic Type of study: Guideline / Prognostic_studies / Qualitative_research Aspects: Patient_preference Limits: Child / Humans Language: En Journal: Br J Dermatol Year: 2018 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Dermatitis, Atopic Type of study: Guideline / Prognostic_studies / Qualitative_research Aspects: Patient_preference Limits: Child / Humans Language: En Journal: Br J Dermatol Year: 2018 Document type: Article Affiliation country: Reino Unido Country of publication: Reino Unido